Ilene Weintraub Yohay, MD
Endocrinology, Diabetes & Metabolism · Flossmoor, ILNPI 1669486262
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,000 of the $21,440 with a category attached, or 65.3%. AstraZeneca accounts for 71.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $11,601 and has fallen 91.8% since, to $950 in 2025.
Across 220 payments — averaging $97.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Abbott$3K
- Insulet Corporation$604
- Novo Nordisk$519
- Medtronic$335
- Mannkind Corporation$330
- plus $2K from 23 others
What the payments were for
- Consulting fees$2,10010%
- Speaking & faculty fees$14,00065%
- Travel & lodging$2481%
- Food & beverage$4,75522%
- Education$2781%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 41 | $15,394 |
| Abbott | 39 | $2,719 |
| Insulet Corporation | 13 | $604 |
| Novo Nordisk | 41 | $519 |
| Medtronic | 5 | $335 |
| Mannkind Corporation | 8 | $330 |
| Lilly USA, LLC | 16 | $279 |
| Amgen(2 entities) | 4 | $208 |
| Sanofi-aventis U.S. LLC | 6 | $173 |
| AbbVie | 9 | $156 |
| Bayer | 8 | $149 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $91 |
| Ascensia Diabetes Care US Inc. | 4 | $69 |
| Corcept Therapeutics | 3 | $55 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| OPKO Pharmaceuticals, LLC | 3 | $46 |
| Sequel Med Tech, LLC | 2 | $42 |
| Dexcom, Inc. | 1 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| Radius Health, Inc. | 2 | $29 |
| Novartis | 1 | $22 |
| Boehringer Ingelheim | 1 | $16 |
| Companion Medical, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| BETA Bionics, Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$14,446
- FREESTYLE LIBRE 3$2,205
- Strensiq$270
- Omnipod$229
- MINIMED 780G$128
- JARDIANCE$120
- AFREZZA$113
- TZIELD$105
How this compares
$21,440 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 444 | $851,514 |
| MounjaroTirzepatide | 251 | $366,907 |
| JardianceEmpagliflozin | 189 | $266,860 |
| FarxigaDapagliflozin Propanediol | 169 | $220,293 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 140 | $213,825 |
| TrulicityDulaglutide | 111 | $170,969 |
| Humalog Kwikpen U-200Insulin Lispro | 41 | $108,610 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $30,795 |
| RybelsusSemaglutide | 17 | $29,387 |
| JanuviaSitagliptin Phosphate | 17 | $25,199 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $24,927 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $21,828 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $21,542 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $20,308 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $18,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $519 | $910,833492 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $279 | $551,178405 claims |
| Boehringer IngelheimJardiance | $16 | $266,860189 claims |
| AstraZenecaFarxiga | $15,394 | $220,293169 claims |
| MerckJanuvia | $11 | $25,19917 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $173 | $12,21612 claims |
| AbbVieSynthroid, Armour Thyroid | $156 | $9,690110 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $52 | $3,900361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Flossmoor
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.